Immune ResponsePreliminary data from the breast cancer vaccine study are encouraging, with over 70% of patients showing a protocol-defined immune response.
Intellectual PropertyThe United States Patent and Trademark Office issued a patent that covers the company’s breast cancer vaccine technology, extending the IP protection into the mid-2040s.
Vaccine DevelopmentAnixa Biosciences has initiated the transfer of the Investigational New Drug application to support the upcoming Phase 2 trial of its breast cancer vaccine, following positive preliminary results from the Phase 1 trial.